Literature DB >> 8968083

Double knockout of the MRP gene leads to increased drug sensitivity in vitro.

A Lorico1, G Rappa, R A Flavell, A C Sartorelli.   

Abstract

Overexpression of the multidrug resistance-associated protein (MRP) gene has been implicated in the resistance of tumor cell lines to a wide array of chemotherapeutic agents, but its normal physiological function(s) remains unknown. We have compared the sensitivity to chemotherapeutic drugs and toxins of wild-type W9.5 embryonic stem cells (ES) and of single and double MRP gene knockout cells derived therefrom. MRP expression was totally abrogated in the double knockout cell line and partially abrogated in the single knockout cell line. Reverse transcription-PCR analyses demonstrated that the MDR1, MDR2, and MDR3 genes were not expressed in either wild-type or MRP knock-out cells. The cytotoxic activities of etoposide, teniposide, vincristine, doxorubicin, daunorubicin, and sodium arsenite were significantly greater in double knockout cells than in parental wild-type ES cells; single knockout ES cells displayed an intermediate level of sensitivity. In contrast, no difference in sensitivity to colchicine and 1-beta-D-arabinofuranosylcytosine existed between the cell lines. Etoposide accumulation in double knockout ES cells was 2-fold higher than in wild-type ES cells. These findings indicate that baseline MRP expression has the capacity to exert a protective role against the toxicity of multiple chemotherapeutic agents and natural toxins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968083

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  MRP subfamily transporters and resistance to anticancer agents.

Authors:  G D Kruh; H Zeng; P A Rea; G Liu; Z S Chen; K Lee; M G Belinsky
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

Review 2.  Physiologic and anatomic characterization of the brain surface glia barrier of Drosophila.

Authors:  Michael K DeSalvo; Nasima Mayer; Fahima Mayer; Roland J Bainton
Journal:  Glia       Date:  2011-02-23       Impact factor: 7.452

Review 3.  Present state and future perspectives of using pluripotent stem cells in toxicology research.

Authors:  Anna M Wobus; Peter Löser
Journal:  Arch Toxicol       Date:  2011-01-12       Impact factor: 5.153

4.  Repression of Zeb1 and hypoxia cause sequential mesenchymal-to-epithelial transition and induction of aid, Oct4, and Dnmt1, leading to immortalization and multipotential reprogramming of fibroblasts in spheres.

Authors:  Yongqing Liu; Partha Mukhopadhyay; M Michele Pisano; Xiaoqin Lu; Li Huang; Qingxian Lu; Douglas C Dean
Journal:  Stem Cells       Date:  2013-07       Impact factor: 6.277

Review 5.  Biomedical and clinical promises of human pluripotent stem cells for neurological disorders.

Authors:  Nopporn Jongkamonwiwat; Parinya Noisa
Journal:  Biomed Res Int       Date:  2013-09-22       Impact factor: 3.411

Review 6.  Human Embryonic Stem Cells: A Model for the Study of Neural Development and Neurological Diseases.

Authors:  Piya Prajumwongs; Oratai Weeranantanapan; Thiranut Jaroonwitchawan; Parinya Noisa
Journal:  Stem Cells Int       Date:  2016-04-28       Impact factor: 5.443

7.  Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer.

Authors:  Lili Ji; Hui Li; Pan Gao; Guoguo Shang; Donna D Zhang; Nong Zhang; Tao Jiang
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

8.  Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure.

Authors:  Consolación Melguizo; Jose Prados; Raquel Luque; Raúl Ortiz; Octavio Caba; Pablo J Alvarez; Beatriz Gonzalez; Antonia Aranega
Journal:  Int J Mol Sci       Date:  2012-12-05       Impact factor: 5.923

9.  Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP).

Authors:  D R Hipfner; M Gao; G Scheffer; R J Scheper; R G Deeley; S P Cole
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.